Recognizing the impact of tardive dyskinesia (TD) on patients

Regardless of severity, TD can cause debilitating complications in multiple aspects of life1,2

Patients with TD have displayed symptoms that range from impairment of gait and posture, speech and eating problems, challenges with psychosocial adjustment, and suicidal thoughts, to worsening anxiety and depression.

Keep in mind that TD affects patients beyond just involuntary movements2-6:

Two people                  talking icon.

Social factors

  • Social isolation
  • Fewer employment opportunities
Person with
                  hotspots on
                  body icon.

Biological and physical factors

  • Pain
  • Dental and gait issues
  • Speech impairment
  • Labored breathing
  • Difficulty eating
Brain

Psychological factors

  • Antipsychotic drug (APD) dose reduction may worsen the underlying condition, while subsequent APD dose increase worsens the TD
  • Overall, this cycle can lead to poor response to treatment and risk of relapse/readmission
  • Worsening anxiety and depression

LEARN MORE: EVALUATING THE IMPACT
OF TD

There are no data to suggest that AUSTEDO affects any of the outcomes on this page.

TD Talks Logo.

Watch Amber Hoberg, PMHNP-BC, discuss the importance of assessing and managing TD


Gray video icon.

Mechanism of Disease:

Learn more about how APD use affects dopamine signaling in TD.5

REFERENCES: 1. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-176. 2. Yassa R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989;80(1):64-67. 3. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580-1588. 4. Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectr. 2018;23(6):370-377. 5. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (NY). 2013;3:tre-03-161-4138-1. 6. Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785-794. 7. Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90(12):1317-1323.